Press Release
<< Back
Verastem Oncology to Participate in Upcoming Investor Conferences
-
H.C. Wainwright 25th AnnualGlobal Investment Conference ; podium presentation onTuesday, September 12, 2023 at2:00 p.m. ET -
2023
Cantor Global Healthcare Conference ; fireside chat onTuesday, September 26, 2023 at9:55 a.m. ET
A live webcast of the presentation and fireside chat will be available on the investors section of the Company’s website at www.verastem.com. An archived replay of the presentation and fireside chat will be made available on the same website for approximately 90 days following each event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905929024/en/
Investors:
Investor Relations
+1 781-469-1694
dcalkins@verastem.com
+1 212-600-1902
ryan.porter@argotpartners.com
Media:
Corporate Communications
+1 (781) 292-4502
lbuffington@verastem.com
Source: Verastem Oncology